The mAb JAA-F11, developed by Rittenhouse-Diakun et al. [231], an IgG3 specific to the TF-α, demonstrated tumor growth inhibition and a decrease in lung metastasis in the breast cancer metastatic model 4T1 [232]. This evidence concerns the gene IGHG3 and breast carcinoma.